VIMKUNYA Chikungunya Vaccine Shows Consistent Safety Profile in Early Real-World Use
Key Insights
VIMKUNYA (search), a non-live virus-like particle vaccine for chikungunya prevention, has shown no serious adverse events in early real-world use since its February 2025 U.S. approval.
Only three non-serious adverse events have been reported to VAERS as of September 2025, including vasovagal syncope (search) and mild skin reactions in two patients.
The vaccine is now available in the United States, European Union, and United Kingdom, with Germany and France being the first European countries to launch the product.
VIMKUNYA (search) (Chikungunya Vaccine, Recombinant), the first approved vaccine for preventing chikungunya virus (search) disease, has demonstrated a reassuring safety profile in early real-world use that aligns with clinical trial findings. Since its U.S. approval in February 2025, no serious adverse events, hospitalizations, or deaths have been reported following vaccine administration.
Post-Marketing Safety Surveillance
As of September 3, 2025, the Vaccine Adverse Event Reporting System (VAERS) has recorded only three non-serious adverse events in two individuals who received VIMKUNYA (search). The first patient experienced a vasovagal syncope (search) episode, while the second patient reported erythema (search) and skin warmth at the injection site.
In the European Union and European Economic Area, where Germany became the first country to make VIMKUNYA (search) available in May 2025, followed by France, no adverse events have been reported to EudraVigilance, the region's pharmacovigilance system.
Clinical Trial Safety Profile
The early real-world safety data mirrors findings from two pivotal Phase 3 clinical trials. In clinical studies, the most common solicited adverse reactions in individuals aged 12 through 64 years were pain at the injection site (23.7%), fatigue (search) (19.9%), headache (search) (18%), and myalgia (search) (17.6%). Among individuals 65 years and older, the most commonly reported reactions were injection site pain (5.4%), myalgia (6.3%), and fatigue (6.3%).
Vaccine Technology and Regulatory Status
VIMKUNYA (search) is a non-live, virus-like particle (VLP) vaccine indicated for preventing disease caused by chikungunya virus (search) in individuals 12 years of age and older. The vaccine utilizes the same VLP technology as other licensed vaccines against hepatitis B and human papillomavirus, which have accumulated decades of post-marketing safety data.
The vaccine received approval under the FDA's accelerated approval pathway based on anti-chikungunya virus (search) neutralizing antibody levels. Continued approval may depend on verification of clinical benefit in a confirmatory trial.
Global Availability and Monitoring
VIMKUNYA (search) is currently approved for use in the United States, European Union/European Economic Area, and the United Kingdom. Additional European countries are expected to launch the vaccine shortly.
While the exact number of administered doses remains difficult to estimate, health authorities emphasize that continued surveillance is essential as vaccine uptake increases. As more doses are administered, some adverse event reports may be expected, particularly given the heightened scrutiny on chikungunya vaccine safety.
The early safety data strengthens confidence in vaccination as a tool for protecting individuals from chikungunya, a potentially debilitating mosquito-borne disease that can cause severe joint pain (search) and long-term complications.